Abstract
Seizures are a known adverse effect of clozapine therapy. The literature varies on incidence rates of seizures, secondary to varying time frames in which each seizure occurred. Tonic-clonic seizures comprise the majority of seizures experienced secondary to clozapine use, but it is imperative to recognize the potential variety of seizure presentation. The exact etiology of clozapine-induced seizure is unknown. Conflicting reports regarding total oral dose, serum concentration, dose titration, and concomitant medications make it difficult to identify a single cause contributing to seizure risk. Following seizure occurrence, it may be in the best interests of the patient to continue clozapine treatment. In this clinical situation, the use of an antiepileptic drug (AED) for seizure prophylaxis may be required. The AED of choice appears to be valproate, but several successful case reports also support the use of lamotrigine, gabapentin and topiramate. Well-designed clinical trials regarding clozapine seizure prophylaxis are lacking. Given clozapine’s strong evidence for efficacy in the treatment of schizophrenia and schizoaffective disorder, every attempt to manage side effects, including seizure, should be implemented to allow for therapeutic continuation.
Similar content being viewed by others
References
Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology. 1991;41(3):369–71.
Caetano D. Use of anticonvulsants as prophylaxis for seizures in patients on clozapine. Australas Psychiatry. 2014;22(1):78–82. doi:10.1177/1039856213502829.
Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008;23(Suppl 1):15–26.
Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15(1):33–48.
Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure. 2010;19(2):69–73. doi:10.1016/j.seizure.2009.11.005.
Novartis Pharmaceuticals Corporation. Clozaril® (clozapine). Prescribing information. Revised 11/2013. http://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf. Accessed 25 Aug 2014.
Conca A, Beraus W, Konig P, Waschgler R. A case of pharmacokinetic interference in comedication of clozapine and valproic acid. Pharmacopsychiatry. 2000;33(6):234–5.
Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci. 1994;6(3):250–6.
Kohlrausch FB, Severino-Gama C, Lobato MI, Belmonte-de-Abreu P, Carracedo A, Hutz MH. The CYP1A2-163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients. Psychiatry Res. 2013;209(2):242–5. doi:10.1016/j.psychres.2013.02.030.
Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry. 1994;55(Suppl B):153–6.
Freudenreich O, Weiner RD, McEvoy JP. Clozapine induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry. 1997;42(2):132–7.
Liukkonen J, Koponen HJ, Nousiainen U. Clinical picture and long-term course of epileptic seizures that occur during clozapine treatment. Psychiatry Res. 1992;44(2):107–12.
Malow BA, Reese KB, Sato S, Bogard PJ, Malhotra AK, Su TP, Pickar D. Spectrum of EEG abnormalities during clozapine treatment. Electroencephalogr Clin Neurophysiol. 1994;91(3):205–11.
Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry. 2007;52(7):457–63.
Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology. 1994;44(12):2247–9.
Bak Th, Bauer M, Schaub RT, Hellweg R, Reischies FM. Myoclonus in patients treated with clozapine: a case series. J Clin Psychiatry. 1995;56(9):418–22.
Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q. 1992;63(1):51–70.
Berman I, Zalma A, DuRand CJ, Green AI. Clozapine-induced myoclonic jerks and drop attacks. J Clin Psychiatry. 1992;53(9):329–30.
Fitzsimons J, Berk M, Lambert T, Bourin M, Dodd S. A review of clozapine safety. Expert Opin Drug Saf. 2005;4(4):731–44.
Gouzoulis E, Ozdaglar A, Kasper J. Myoclonic seizures followed by grand mal seizures during clozapine treatment. Am J Psychiatry. 1993;150(7):1128.
Usiskin SI, Nicolson R, Lenane M, Rapoport JL. Gabapentin prophylaxis of clozapine-induced seizures. Am J Psychiatry. 2000;157(3):482–3.
Taner E, Cosar B, Isik E. Clozapine-induced myoclonic seizures and valproic acid. Int J Psychiatry Clin Pract. 1998;2:53–5.
Geaney D. Clozapine can cause hallucinations by inducing complex partial seizures of temporal lobe origin (temporal lobe epilepsy). A potentially serious complication in the management of schizophrenia with clozapine. J Psychopharmacol. 1995;9(1):64–6. doi:10.1177/026988119500900110.
Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract. 2005;11(5):289–301.
Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013;74(6):603–13. doi:10.4088/JCP.12r08064 (quiz 613).
Freedman JE, Wirshing WC, Russell AT, Bray MP, Unutzer J. Absence status seizures during successful long term clozapine treatment of an adolescent with schizophrenia. J Child Adolesc Psychopharmacol. 1994;4(1):53–62.
Jarbin H, Johansson BA, Lundgren J. Clozapine and therapy-refractory epileptic seizures. Eur Child Adolesc Psychiatry. 2001;10(3):209–10.
Langosch JM, Trimble MR. Epilepsy, psychosis and clozapine. Hum Psychopharmacol. 2002;17(2):115–9.
Centorrino F, Price BH, Tuttle M, Bahk WM, Hennen J, Albert MJ, Baldessarini RJ. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry. 2002;159(1):109–15.
Chung SJ, Jeong SH, Ahn YM, Kang UG, Koo YJ, HA JH, Lee SG, Kim YS. A retrospective study of clozapine and electroencephalographic abnormalities in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(1):139–44.
Varma S, Bishara D, Besag FM, Taylor D. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol. 2011;1(2):47–66. doi:10.1177/2045125311405566.
Naber D. Optimizing clozapine treatment. J Clin Psychiatry. 1999;60(Suppl 12):35–8.
Sajatovic M, Meltzer HY. Clozapine-induced myoclonus and generalized seizures. Biol Psychiatry. 1996;39(5):367–70.
Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet. 1997;32(2):93–100.
Simpson GM, Cooper TA. Clozapine plasma concentrations and convulsions. Am J Psychiatry. 1978;135:99–100.
Funderburg LG, Vertrees JE, True JE, Miller AL. Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry. 1994;151(12):1840–1.
Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013;28(1):50–6. doi:10.1097/YIC.0b013e32835ac9da.
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195–235. doi:10.1055/s-0031-1286287.
Greenwood-Smith C, Lubman DI, Castle DJ. Serum clozapine levels: a review of their clinical utility. J Psychopharmacol. 2003;17(2):234–8.
Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold. Psychopharmacology (Berl). 2013;225(3):505–18. doi:10.1007/s00213-012-2922-7.
Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H, Fleischhacker WW. EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology (Berl). 1994;114(1):97–100.
Stark A, Scott J. A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry. 2012;46(9):816–25. doi:10.1177/0004867412438871.
Ifteni P, Nielsen J, Burtea V, Correll CU, Kane JM, Manu P. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand. 2014;130(1):25–9. doi:10.1111/acps.12241.
Ifteni P, Correll CU, Nielsen J, Burtea V, Kane JM, Manu P. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord. 2014;166:168–72. doi:10.1016/j.jad.2014.04.020.
Haberfellner EM. Myoclonic and generalized tonic-clonic seizures during combined treatment with low doses of clozapine and haloperidol. Eur Psychiatry. 2002;17(1):55–6.
Garcia G, Crismon ML, Dorson PG. Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol. 1994;14(6):426–8.
Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol. 2000;56(8):585–9.
DuMortier G, Lochu A, Colen de Melo P, Ghribi O, Roche-Rabreau D, DeGrassat K, Desce JM. Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry. 1996;153(5):738–9.
Chapman S, Ragg M, McGeechan K. Citation bias in reported smoking prevalence in people with schizophrenia. Aust N Z J Psychiatry. 2009;43(3):277–82. doi:10.1080/00048670802653372.
de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2–3):135–57.
Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol. 2001;21(6):569–74.
McCarthy RH. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry. 1994;27(5):210–1.
Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry. 1994;55(6):255–7.
Almeida J, Serrão EM, Almeida AT, Afonso JG. Effective treatment with clozapine and valproate for refractory schizophrenia-like psychosis after cerebellar hemorrhage. Clin Neuropharmacol. 2011;34(3):131–2.
Meltzer HY, Ranjan R. Valproic acid treatment of clozapine-induced myoclonus. Am J Psychiatry. 1994;151(8):1246–7.
Guha P, Nizamie HS. Refractory schizophrenia, clozapine and epilepsy: management strategies. Indian J Psychiatry. 1998;40(1):84–6.
Foster R, Olajide D. A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care. J Psychopharmacol. 2005;19(1):93–6.
Sparshatt A, Whiskey E, Taylor D. Valproate as prophylaxis for clozapine-induced seizures: a survey of practice. Psychiatr Bull. 2008;32:262–5. doi:10.1192/pb.bp.107.019174.
Wirshing WC, Ames D, Bisheff S, Pierre JM, Mendoza A, Sun A. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol. 1997;17(2):120–1.
Madeb R, Hirschmann S, Kurs R, Turkie A, Modai I. Combined clozapine and valproic acid treatment-induced agranulocytosis. Eur Psychiatry. 2002;17(4):238–9.
Muzyk A, Gala G, Kahn DA. Use of lamotrigine in a patient with a clozapine-related seizure. J Psychiatr Pract. 2010;16(2):125–8.
Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res. 2012;141(2–3):173–8.
Landry P. Gabapentin for clozapine-related seizures. Am J Psychiatry. 2001;158(11):1930–1.
Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry. 2000;45(2):198.
Navarro V, Pons A, Romero A, Bernardo M. Topiramate for clozapine-induced seizures. Am J Psychiatry. 2001;158(6):968–9.
Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16(4):368–74.
Logothetis J. Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology. 1967;17(9):869–77.
Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25(2):91–110.
Otsuka America Pharmaceutical, Inc. Abilify® (aripiprazole). Prescribing information. Revised 6/2014. http://www.otsuka-us.com/Documents/Abilify.PI.pdf. Accessed 25 Aug 2014.
Forest Pharmaceuticals, Inc. Saphris® (asenapine). Prescribing information. Revised 8/2014. http://www.frx.com/pi/saphris_pi.pdf. Accessed 25 Aug 2014.
Novartis Pharmaceuticals Corporation. Fanapt® (iloperidone). Prescribing information. Revised 4/2014. http://www.pharma.us.novartis.com/product/pi/pdf/fanapt.pdf. Accessed 25 Aug 2014.
Sunovion Pharmaceuticals Inc. Latuda® (lurasidone HCl). Prescribing information. Revised 7/2013. http://www.latuda.com/LatudaPrescribingInformation.pdf. Accessed 25 Aug 2014.
Eli Lilly and Company. Zyprexa® (olanzapine). Prescribing information. Revised 7/2013. http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed 25 Aug 2014.
Janssen Pharmaceuticals, Inc. Invega® (paliperidone). Prescribing information. Revised 4/2014. http://www.janssencns.com/invega-prescribing-information. Accessed 25 Aug 2014.
AstraZeneca. Seroquel® (quetiapine fumarate). Prescribing information. Revised 10/2013. http://www1.astrazeneca-us.com/pi/Seroquel.pdf. Accessed 25 Aug 2014.
AstraZeneca. Seroquel XR® (quetiapine fumarate). Prescribing information. Revised 10/2013. http://www.azpicentral.com/seroquel-xr/seroquelxr.pdf#page=1. Accessed 25 Aug 2014.
Janssen Pharmaceuticals, Inc. Risperdal® (risperidone). Prescribing information. Revised 4/2014. http://www.janssenpharmaceuticalsinc.com/assets/risperdal.pdf. Accessed 25 Aug 2014.
Pfizer, Inc. Geodon® (ziprasidone HCl). Prescribing information. Revised 1/2014. http://labeling.pfizer.com/ShowLabeling.aspx?id=584#page=1. Accessed 25 Aug 2014.
Disclosures
Both Andrew M. Williams and Susie H. Park have nothing to disclose and report no conflicts of interest. This manuscript received no funding.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Williams, A.M., Park, S.H. Seizure Associated with Clozapine: Incidence, Etiology, and Management. CNS Drugs 29, 101–111 (2015). https://doi.org/10.1007/s40263-014-0222-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-014-0222-y